以杯芳烃为载体的AhR激动剂用于放射性肠炎的研究

AhR agonists based on calixarene as carriers for the treatment of radiation-induced enteritis

  • 摘要:
    目的 研究肠道偶氮还原酶激活的偶氮杯4芳烃azoC4A结合芳香烃受体(AhR)激动剂β-萘黄酮(BNF)对小鼠放射性肠炎(RIE)的治疗作用。
    方法 采用荧光滴定法测定偶氮杯4芳烃与AhR激动剂BNF的主客体识别能力。采用AhR报告基因细胞系HepG2检测主客体识别复合物对AhR的激活能力。动物实验将24只雌性C57BL/C小鼠采用随机区组法分为4组,分别为单纯照射组、azoC4A组、BNF组和azoC4A-BNF组,每组6只,纯化饮食1周后,BNF组、azoC4A组、azoC4A-BNF组分别每天灌胃给药BNF(15 mg/kg)、azoC4A(84 mg/kg)、azoC4A-BNF(BNF等效剂量15 mg/kg)。给药7 d后,小鼠腹部进行15 Gy Cs137 γ射线照射,照射后第3天处死小鼠,收集结肠、小肠和血液样本。采用实时定量PCR法检测肠道组织中AhR的激活水平,同时评估RIE的炎症因子水平以及肠道病理的变化。组间比较采用单因素方差分析(One-way ANOVA),符合正态分布的计量资料的组间两两比较采用Student t检验。
    结果 荧光滴定结果显示AhR激动剂BNF与azoC4A的非共价结合系数为6×107 M−1,且当azoC4A与BNF的浓度比为3:2时,二者的结合率达到80%。AhR-Luc HepG2细胞进行荧光素酶报告基因实验中,azo4CA-BNF组的自发光强度明显低于BNF组(125±13对 288±17,t=13.220,P<0.001),但azo4CA-BNF组的自发光强度与对照组的差异无统计学意义(125±13对79±30,t=2.481,P=0.070)。azoC4A-BNF组小鼠结肠的长度明显大于单纯照射组(49.6±2.9) mmol/L 对(44.8±3.4) mmol/L,t=2.400,P<0.05)。与单纯照射组比较,azoC4A-BNF组、BNF组血浆中的二胺氧化酶含量均明显降低,(132.5±40) U/L对(32.8±22.4) U/L对(27.6±7.8) U/L,t=4.399、3.731,均P<0.05,同时azoC4A-BNF组TNF-α的含量也较对照组明显下降(13.49±2.26)pg/ml对(9.05±4.94)pg/ml,t=2.721,P=0.035。azoC4A-BNF组小鼠肠道组织中Cyp1a1的表达量为BNF组的8倍、单纯照射组的431倍(8.49±1.08对5.49±0.83 对−0.30±1.08);与单纯照射组比较,azoC4A-BNF组和BNF组的差异均有统计学意义(t=3.430、3.018,均P<0.05)。
    结论 通过非共价结合的方式将偶氮杯芳烃与AhR激动剂BNF相结合,取得了对小鼠RIE损伤的治疗效果。同时偶氮杯芳烃作为水溶性的载体,解决了AhR激动剂水溶性和靶向性差的问题,为AhR配体的应用提供了新的思路。

     

    Abstract:
    Objective To investigates the radiation protective effect of azo-calix4arene (azoC4A) activated by gut azo-reductase and combined with the AhR agonist β-naphthoflavone (BNF) in mice with radiation-induced enteritis.
    Methods The non-covalent binding ability of azo-calix4arene and the AhR agonist BNF was determined using fluorescence titration. The AhR activation capability of the host-guest recognition complex was evaluated in the AhR reporter gene cell line HepG2. For the animal experiments, 24 female C57BL/C mice were randomly divided into 4 groups (single irradiation group, azoC4A group, BNF group, and azoC4A-BNF group, 6 mice per group). After one week of purified diet, the mice were gavaged daily with BNF (15 mg/kg), azoC4A(84 mg/kg)or azoC4A-BNF (equivalent BNF dose, 15 mg/kg). After 7 days of dosing, the mice were irradiated with Cs137 γ-rays at a dose of 15 Gy. On the third day post-irradiation, the mice were euthanized, and samples of the colon, small intestine, and blood were collected. RT-PCR was used to assess AhR activation levels in intestinal tissues, while inflaatory markers and pathological changes in the gut were evaluated. Data were analyzed using one-way ANOVA, and pairwise comparisons were made with the Student′s t-test.
    Results Fluorescent titration results indicated that the non-covalent binding constant of the AhR agonist BNF with azoC4A was 6×107 M−1. The binding reached 80% when the concentration ratio of azoC4A to BNF was 3∶2. In the AhR-Luc HepG2 cell-based luciferase reporter gene assay, the spontaneous luminescence intensity of the azoC4A-BNF group was significantly lower than that of the BNF group (125±13 vs. 288±17, t=13.220, P<0.001), and there was no statistically significant difference compared to the Ctrl group (125±13 vs. 79±30, t=2.481, P=0.0704). The length of colon was significantly higher in the azoC4A-BNF complex group than that of the single irradiation group in the mouse (49.6±2.9) mmol/L vs.(44.8±3.4) mmol/L, t=2.400, P<0.05) . Furthermore, the plasma Diamine oxidase(DAO) content was significantly lower in the azoC4A-BNF group and the BNF group compared with the radiation group (32.8±22.4) U/L vs. (27.6±7.8) U/L vs. (132.5±40) U/L; t=4.399, 3.731; P<0.05. Meanwhile, the TNF-α level in the azoC4A-BNF group also decreased significantly (13.49±2.26) pg/ml vs. (9.05±4.94) pg/ml, t=2.721, P=0.035. Furthermore, the gene expression level of Cyp1a1 in the mouse intestine of the azoC4A-BNF group was found to be 8-folds higher than that observed in the BNF group and 431-folds higher than the radiation group (8.49±1.08 vs. 5.49±0.83 vs.-0.30±1.08; t=3.430, 3.018; both P<0.05). Conclusions The non-covalent binding of azo-calixarenes with the AhR agonist BNF was utilized to achieve therapeutic effects on radiation-induced intestinal injury in mice. At the same time, the azo-calixarenes, as a water-soluble carrier, solved the issues of poor solubility and targeting of AhR agonists, providing a new approach for the application of AhR ligands.

     

/

返回文章
返回